Adult patients with an ischemic stroke in the past 24 hours causing arm or leg weakness were eligible. Exclusion criteria included modified Rankin Scale score >3, thrombolysis for index event, and significant comorbidity. Participants were recruited from Derby Teaching Background and Purpose-Repeated episodes of limb ischemia and reperfusion (remote ischemic conditioning [RIC]) may improve outcome after acute stroke. Methods-We performed a pilot blinded placebo-controlled trial in patients with acute ischemic stroke, randomized 1:1 to receive 4 cycles of RIC within 24 hours of ictus. The primary outcome was tolerability and feasibility. Secondary outcomes included safety, clinical efficacy (day 90), putative biomarkers (pre-and post-intervention, day 4), and exploratory hemodynamic measures. Results-Twenty-six patients (13 RIC and 13 sham) were recruited 15.8 hours (SD 6.2) post-onset, age 76.2 years (SD 10.5), blood pressure 159/83 mm Hg (SD 25/11), and National Institutes of Health Stroke Scale (NIHSS) score 5 (interquartile range, 3.75-9.25). RIC was well tolerated with 49 out of 52 cycles completed in full. Three patients experienced vascular events in the sham group: 2 ischemic strokes and 2 myocardial infarcts versus none in the RIC group (P=0.076, log-rank test). Compared with sham, there was a significant decrease in day 90 NIHSS score in the RIC group, median NIHSS score 1 (interquartile range, 0.5-5) versus 3 (interquartile range, 2-9.5; P=0.04); RIC augmented plasma HSP27 (heat shock protein 27; P<0.05, repeated 2-way ANOVA) and phosphorylated HSP27 (P<0.001) but not plasma S100-β, matrix metalloproteinase-9, endocannabinoids, or arterial compliance. 
A pplying an ischemic stimulus distant from the brain (remote ischemic conditioning [RIC] , eg, transient limb ischemia) after a stroke can induce neuroprotection. 1 The mechanisms of action underlying this are unclear; the production of a chemical messenger released from the hypoxic limb has been implicated, for example, NO, bradykinin, adenosine, heat-shock proteins, and endocannabinoids. 2, 3 RIC is an attractive prospect because it bears minimal cost and would be simple to administer. It may decrease stroke risk in patients with intracranial arterial stenosis, and applying RIC in prehospital stroke patients is feasible. 4, 5 Furthermore, preliminary studies of RIC in patients with acute myocardial infarction are encouraging. 6 In the current study, we aimed to demonstrate tolerability and feasibility of RIC in patients presenting to hospital with acute stroke while simultaneously investigating potential mechanisms of action.
Methods

Trial Design
The RECAST (Remote Ischemic Conditioning After Stroke Trial) was a single-center, randomized, outcome-blinded, placebo-controlled trial (ISRCTN 86672015).
Hospitals NHS Foundation Trust, United Kingdom, between March 2013 and July 2015.
Randomization and Intervention
In addition to standard care (single antiplatelets, blood pressure, and cholesterol reduction), RIC was performed on the stroke unit immediately after randomization (web-based, 1:1, minimized on age, sex, National Institutes of Health Stroke Scale [NIHSS] score, and systolic blood pressure). Intervention: 4 cycles of intermittent limb ischemia; alternating 5 minutes inflation (20 mm Hg above systolic blood pressure) and 5 minutes deflation performed manually using a standard upper arm blood pressure cuff in the nonparetic arm. Patient position was not specified. The control group received a sham procedure (cuff inflation to 30 mm Hg).
Primary Outcome
The primary outcome was tolerability and feasibility of RIC after acute ischemic stroke.
Secondary Outcomes
Blood samples were collected (pre-RIC, post-RIC, and day 4) for surrogate markers of efficacy (plasma S100-β, matrix metalloproteinase-9, troponin T), inflammation (C-reactive protein), and other putative biomarkers (HSP [heat shock proteins] and endocannabinoids). Transcranial Doppler was performed as a continuous beatto-beat recording during the intervention; central pressures measured with Sphygmocor. 7 Serious adverse events, modified Rankin Scale score, impairment (NIHSS score and motricity index), Barthel index, extended activities of daily living, Zung depression scale, and cognition (Mini-Mental State Examination) were measured at day 90. Statistical tests are described in Figure 2 and the online-only Data Supplement.
Sample Size
Assuming a meaningful delivery of RIC of at least three of the four 5-minute cycles, 26 patients gives 90% power to reject the null hypothesis that intervention and sham are equally tolerated (SD 4 minutes and α=0.05). The original sample size was rounded to 30, but with no losses to follow-up or crossovers, recruitment was stopped at 26.
Results
Twenty-six participants were recruited during 27 months ( Figure 1 ). All participants had an average age of 76 years; mean blood pressure of 159/83 mm Hg, and median NIHSS score of 5 (Table) . More participants in the control group had diabetes mellitus (5 versus 0; P=0.04, Fisher exact test), and time to randomization was 15.8 hours.
Tolerability
RIC was well tolerated: 49 out of 52 cycles were completed in full. One participant was intolerant of RIC (because of cuff pressure), with an overall mean difference between groups of 46 seconds (P=0.33). All patients tolerated the sham procedure. Eight (5 RIC and 3 sham) of 26 participants correctly stated at day 90 the intervention they received at randomization.
Adverse Events
There were no procedure-related serious adverse events (Table  I in the online-only Data Supplement). Three patients experienced vascular events in the control group: 2 ischemic strokes (days 6 and 8) and 2 myocardial infarcts in the same patient (days 1 and 66) versus none in the RIC group (P=0.076, logrank test).
Laboratory Measures
In the RIC group, plasma analysis showed a significant increase in total HSP27 (P<0.05, repeated 2-way ANOVA) and phosphorylated HSP27 (pHSP27; P<0.001; Figure 2 ). HSPs 60, 70, and 90 did not differ between groups or over time. Similarly, plasma C-reactive protein, S100-β, matrix metalloproteinase-9, troponin T, and endocannabinoids did not differ between groups (Figures I and II in the online-only Data Supplement). Data presented are mean (SD), median (interquartile range), or number (%). AF indicates atrial fibrillation; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; and TIA, transient ischemic attack.
Hemodynamic Measures
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Clinical Outcomes
Day 90 modified Rankin Scale score was nonsignificantly lower in the treatment group (2 versus 3; P=0.8; Table II in the online-only Data Supplement). There was a significant decrease in day 90 NIHSS score in the RIC group: median NIHSS score 1 (interquartile range, 0.5-4) versus 3 (interquartile range, 1-4.5; P=0.04 Mann-Whitney U test).
Discussion
The RECAST has demonstrated that RIC is well tolerated after acute stroke and seems safe and feasible. Furthermore, RIC may improve neurological outcome and reduce vascular event rates evidenced by a significant improvement in NIHSS score and a trend to fewer vascular events by day 90. Biomarker studies suggest that protective mechanisms may be mediated through phosphorylated HSP27. There were no serious adverse events relating to RIC with only one patient reducing treatment because of cuff pressure intolerance. Prehospital RIC after acute stroke seems feasible, but at least 18% of patients had a transportation time too short for 4 full cycles (the procedure was discontinued on arrival). 4 The primary outcome, penumbral salvage, did not improve with RIC, but there were more TIAs and less severe strokes on arrival to hospital in the per-conditioned group. 4 The absence of baseline measurements and an imbalance at randomization confounds interpretation of their results. Numerous messengers have been implicated in ischemic conditioning, and we have demonstrated that RIC causes a significant increase in serum total HSP27 and phosphorylated HSP27 (pHSP27) 4 days after intervention, compared with control. Human HSP27 is neuroprotective in experimental stroke, and infarct volume reduction is enhanced if HSP is in a phosphorylated form. 8 Preclinical models have shown benefit using RIC ≤6 hours post-ictus, 1 but the role of RIC in the current trial is unlikely to be neuroprotective as the intervention was too late (16 hours). Inflammation poststroke is a process occurring over hours to days; hence, other potential mechanisms include reducing cerebral edema 1, 3 and inducing ischemic tolerance to recurrent events. Indeed, mice overexpressing HSP27 are protected against cerebral infarction.
3
This trial has several limitations. First, the sample size meant the trial was not powered to detect changes in clinical outcomes, and the differences seen in neurological improvement and the trend to a reduction in vascular events may be because of chance or a greater cardiovascular risk in the control group. Second, participants receiving stroke thrombolysis were not included; the safety of running RIC in parallel with hyperacute stroke treatments requires further investigation, planned in the RECAST-2, an ongoing pilot study (https:// clinicaltrials.gov/ct2/show/NCT02779712). Finally, the longer-term effects of RIC are unknown and should be considered in future trial design; RIC may have both acute and more prolonged effects. 
